【摘要】 目的:探讨Ⅱ期非小细胞肺癌(NSCLC)组织中Ⅲ型β微管蛋白(β-tubulin-Ⅲ)和Stathmin基因mRNA表达与诺维本+顺铂(NP)方案化疗敏感性的关系,为个体化治疗方案的制定提供依据。方法:单基因定量法检测73例已手术Ⅱ期NSCLC患者癌组织中β-tubulin-Ⅲ和Stathmin的mRNA表达。所有患者行NP方案化疗,并随访患者的无瘤生存时间(DFS)和总生存时间(OS),统计学分析β-tubulin-Ⅲ和Stathmin的mRNA表达水平与患者DFS和OS的关系。结果:73例患者的OS与β-tubulin-Ⅲ的mRNA表达水平有关,P=0.003。患者的DFS与β-tubulin-Ⅲ的表达及淋巴结转移情况有关,P<0.01。绘制生存曲线表明,癌组织中β-tubulin-Ⅲ低表达患者的OS和DFS均高于β-tubulin-Ⅲ高表达者,P<0.05;Stathmin低表达患者的OS和DFS与高表达患者相比,差异均无统计学意义,P>0.05。结论:Ⅱ期NSCLC患者癌组织中,β-tubulin-Ⅲ表达水平可以作为预测患者预后及化疗敏感性的指标,可作为选择合适化疗药物的参考。更多还原

【Abstract】 OBJECTIVE: To explore the relationship between chemotherapy sensitivity of patients and the expression level of β-tubulin-Ⅲ and Stathmin mRNA in cancer tissue of Ⅱ period NSCLC,which would provide a basis of the proper medicine choice for the patients’ tailored chemotherapy.METHODS: The expression of β-tubulin-Ⅲ and Stathmin mRNA of 73 NSCLC patients were measured by Quanti-Gene Assay.All patients accepted NP chemotherapy,and follow-up patients with disease-free survival time(DFS) and overall survival(OS).The relationship between the expression level of β-tubulin-Ⅲ,Stathmin mRNA in cancer tissue and prognosis of patients were statistically analyzed.RESULTS: The OS of patients was related with the expression level of β-tubulin-Ⅲin cancer tissue(P=0.003),the DFS of patients was related with the expression level of β-tubulin-Ⅲ and lymph node metastasis(P<0.01).The OS and DFS of patients which had lower expression level of β-tubulin-Ⅲ in cancer tissue were better than patients who had higher expression level(P<0.05).The expression level of Stathmin in cancer tissue was irrelevant with the OS and DFS of patients(P>0.05).CONCLUSION: In patients with Ⅱ period NSCLC,the expression of β-tubulin-Ⅲ in cancer tissue can be a prediction for index of the chemotherapy sensitivity and prognosis,and can be used as a reference to choose the appropriate chemotherapy drugs.更多还原